Planegg, Germany
Planegg, Germany

Time filter

Source Type

Eileen Bird J.,Bristol Myers Squibb | Smith P.L.,Bristol Myers Squibb | Wang X.,Agennix Inc. | Schumacher W.A.,Bristol Myers Squibb | And 3 more authors.
Thrombosis and Haemostasis | Year: 2012

Plasma kallikrein is a multifunctional serine protease involved in contact activation of coagulation. Deficiency in humans is characterised by prolonged activated partial thromboplastin time (aPTT); however, the balance between thrombosis and haemostasis is not fully understood. A study of plasma kallikrein-deficient mice revealed increased aPTT, without prolonged bleeding time. Prekallikrein antisense oligonucleo-tide (ASO) treatment in mice suggested potential for a positive therapeutic index. The current goal was to further define the role of plasma kallikrein in coagulation. Blood pressure and heart rate were normal in plasma kallikrein-deficient mice, and mice were completely protected from occlusion (100 ± 1.3% control flow) in 3.5% FeCl 3 -induced arterial thrombosis versus heterozygotes (20 ± 11.4%) and wild-type litter-mates (8 ± 0%). Vessels occluded in 8/8 wild-type, 7/8 heterozygotes, and 0/8 knockouts. Anti-thrombotic protection was less pronounced in 5% FeCl 3-induced arterial injury. Integrated blood flow was 8 ± 0% control in wild-type and heterozygotes, and significantly (p<0.01) improved to 43 ± 14.2% in knockouts. The number of vessels occluded was similar in all genotypes. Thrombus weight was significantly reduced in knockouts (-47%) and heterozygotes (-23%) versus wild-type in oxidative venous thrombosis. Average tail bleeding time increased modestly in knockout mice compared to wild-type. Average renal bleeding times were similar in all genotypes. These studies confirm and extend studies with prekallikrein ASO, and demonstrate that plasma kallikrein deletion prevents occlusive thrombus formation in mice with a minimal role in provoked bleeding. Additional support for the significance of the intrinsic pathway in the coagulation cascade is provided, as well as for a potential new anti-thrombotic approach. © Schattauer 2012.


Patent
Agennix Inc. | Date: 2011-02-25

The present invention relates to lactoferrin for use in the treatment of severe sepsis. In particular, the present invention relates to methods of effectively treating sepsis, in particular, severe sepsis, by administering orally a composition of lactoferrin (LF). More particularly, the present invention relates to methods of treating prophylactically or therapeutically sepsis, in particular, severe sepsis, by administering orally a composition of lactoferrin to patients with an APACHE II score 25, in particular <25.


Patent
Agennix Inc. | Date: 2011-03-23

The invention pertains to inhibitors of various kinases (e. g. S/T kinases; Tyr kinases etc.) which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described therein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases. Thus the subject kinase inhibitors are useful in treating a wide range of diseases / conditions associated with abnormal functions / excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractrory to other therapeutic agents. Pharmaceutical compositions and packaged pharmaceuticals which instructions of these inhibitors, and methods of using these inhibitors are also provided.


Trademark
Agennix Inc. | Date: 2012-06-28

Pharmaceutical and biopharmaceutical preparations for the treatment of cancer, sepsis, tumors, skin ulcers and bacterial infection and to modulate the immune system. Scientific research and development services in the field of chemistry, biotechnology, bio-pharmaceutics and medical science; technology consultation and research in the field of chemistry, biotechnology, bio-pharmaceutics and medical science; chemical, biochemical, biological and bacteriological research and analysis; preparing biotechnological and biopharmaceutical analysis; pharmaceutical drug development services; biological research; scientific research.


Patent
Agennix Inc. | Date: 2010-02-08

The present invention relates to methods of treating prophylactically or therapeutically bacteremia, sepsis, septic shock or related conditions such as ARDS by administering orally a composition of lactoferrin alone or in combination with standard therapies or metal chelators to prevent or treat the consequences of bacterially induced systemic inflammatory response syndrome. In particular it is claimed that the therapeutic use of recombinant human lactoferrin alone or in combination with metal chelators or other therapeutic interventions decreases the mortality due to bacteremia, sepsis, septic shock or related conditions such as ARDS.


Patent
Agennix Inc. | Date: 2012-10-09

The present invention provides a novel pyrazolo[3,4-d]pyrimidin-4-one, specifically a derivative of 1-(pyridine-4-yl)-pyrazolo[3,4-d]pyrimidin-4-one. This compound is a kinase inhibitor that shows unexpected anti-proliferative activity against cells, including against tumor cells, and anti-tumor activity in xenograft tumor models. The compound or a suitable salt or prodrug thereof is useful for the treatment of individuals suffering from a cancer or another proliferative disorder or disease.


The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.


Patent
Agennix Inc. | Date: 2011-05-12

The present invention provides derivatives of pyrido[2,3-d]pyrimidin-7-one. These compounds are inhibitors or kinases such as Raf, including compounds that show anti-proliferative activity, including against tumor cells, and are useful in the treatment of diseases including cancer.


Patent
Agennix Inc. | Date: 2011-03-23

The invention pertains to inhibitors of various kinases (e. g. S/T kinases; Tyr kinases etc.) which inhibitors are previously known as cyclin dependent kinase inhibitors (CDKs). As described therein, the inhibitors of this invention are capable of inhibiting various wild-type and mutant form kinases, including drug resistant forms of mutant kinases. Thus the subject kinase inhibitors are useful in treating a wide range of diseases / conditions associated with abnormal functions / excessive activities of the target kinases, including mutant kinases. The invention further provides methods for treating cancers, tumors and patients which are resistant or refractrory to other therapeutic agents. Pharmaceutical compositions and packaged pharmaceuticals which instructions of these inhibitors, and methods of using these inhibitors are also provided.


Loading Agennix Inc. collaborators
Loading Agennix Inc. collaborators